Description

PA007162.m2cLA: Recombinant Anti-mouse CD279 (PD-1) Antibody (clone: RMP1-14.1), Mouse IgG2c-L234A L235A P329G (LALAPG) Kappa, In Vivo Grade

The anti-mouse CD279 antibody is a highly specific, affinity-purified monoclonal antibody designed for advanced immunological studies in murine models. Targeting CD279, also known as Programmed Cell Death Protein 1 (PD-1), this antibody is an essential tool for researchers investigating immune checkpoint pathways, T-cell regulation, and cancer immunotherapy. Our anti-mouse CD279 antibody stands out for its exceptional specificity, minimal cross-reactivity, and robust performance across applications like flow cytometry, immunohistochemistry, and Western blotting.

Syd Labs’s in vivo grade recombinant anti-mouse CD279 (PD-1) monoclonal antibody (mouse IgG2c-LALAPG kappa) was produced in mammalian cells. Its affintiy to the mouse PD-1 protein is <2 nM. Recombinant anti-mouse PD-1/CD279 antibody shares identical variable region sequences with the rat anti-mouse PD-1 antibody (Clone: RMP1-14). The constant region of Syd Labs’ Anti-mouse PD-1 Mouse IgG2c-LALAPG Kappa Monoclonal Antibody (Clone RMP1-14.1) is mouse IgG2c-LALAPG Kappa, which can be used in conjunction with the recombinant mouse IgG2c-LALAPG isotype control antibody. Sample preparation conditions and optimal dilution factors should be determined by researchers through experimental optimization.

Anti-mouse PD-1 Mouse IgG2c-L234A L235A P329G (LALAPG) Kappa Monoclonal Antibody (Clone RMP1-14.1) （PA007162.m2cLA Syd Labs）is the recombinant anti-mouse PD-1 antibody (clone RMP1-14.1) whose constant regions are mouse IgG2c LALAPG kappa. We further murinize the antibody variable region sequences of PA007162.m2cLA to produce Recombinant Murinized Anti-mouse PD-1 Mouse IgG2c-L234A L235A P329G (LALAPG) Kappa Monoclonal Antibody (Clone RMP1-14.1) （PA007162.mm2cLA Syd Labs）.

References for anti-mouse CD279 (PD-1) antibody(RMP1-14):

1、The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent.
Grasselly, C., et al. Front Immunol. 2018 Oct 9;9:2100. doi: 10.3389/fimmu.2018.02100. PMID: 30356816
Immune checkpoint inhibitors (ICI), such as anti-PD-1 (Programmed cell death 1) or anti-PD-L1 (Programmed death-ligand 1) antibodies, are among the most important recent breakthroughs in oncology. …The PD-1/PD-L1 axis induces an inhibitory signal in T cells, and PD-1/PD-L1 pathway blockade restores T cell function resulting in increased proliferation and cytotoxic activity, subsequently improving anti-tumor immune response. …For this reason, it is crucial to develop new therapeutic approaches to enhance the therapeutic effects of PD-1/PD-L1 blockade, and to avoid resistance phenomena. …We performed an exploratory study of various combination regimens of chemotherapies with immune checkpoint blockers anti-PD-1 and anti-PD-L1, in several murine syngeneic preclinical models. …T cell infiltrates were increased after exposure to chemotherapy + anti-PD-1, to a stronger extent in the 4T1 model than in the MC38 model.
Tags: anti-mouse PD-1 RMP1-14; anti-mouse PD-1 RMP1-14 mAb

2、A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1.
Ngiow, S. F., et al. Cancer Res. 2015 Sep 15;75(18):3800-11. doi: 10.1158/0008-5472.CAN-15-1082. PMID: 26208901
Purified anti-mouse PD1 mAb (RMP1-14), anti-mouse Tim3 (RMT3-23), anti-mouse PDL1 (10F.9G2), and control Ig (2A3) were purchased from BioXCell and used in the schedule and dose as indicated. …Tumor growth was measured using a digital caliper, and tumor sizes are presented as mean ± SEM. At indicated time points, tumors were weighed and recorded (mg) for individual mice in each group. …For Foxp3+ Treg depletion, 500 ng of DT (200 ?L volume) was intraperitoneally injected in MC38- or AT3-bearing Foxp3-DTR transgenic mice at the indicated time, and an equal volume of PBS was used as a control. …Tumors and peripheral lymphoid tissues were harvested from mice that had been treated with mAb or otherwise and processed for flow cytometric analysis as previously described. …Statistical analyses were conducted using GraphPad Prism software.
Tags: anti-mouse PD-1 RMP1-14 antibody in animal model; anti-mouse PD-1 RMP1-14 mAb in animal model

References about Anti-mouse PD-1 antibody products，please click: anti-mouse PD–1 monoclonal antibody (clone RMP1-14) referenced literature.

Related Recombinant IgG Reference Antibodies:
Recombinant Mouse IgG1 Isotype Control Antibody and Mutants, In vivo Grade
Recombinant Mouse IgG2a Isotype Control Antibody and Mutants, In vivo Grade
Recombinant Mouse IgG2c Isotype Control Antibody and Mutants, In vivo Grade
Recombinant Rat IgG2a Isotype Control Antibody, In vivo Grade

Syd Labs provides the following anti-mouse PD-L1 / PD-1 antibodies:
Recombinant anti-mouse PD1 antibodies (Clone 29F.1A12.1), In vivo grade
Recombinant anti-mouse PD-1 antibodies (Clone RMP1-14.1), In vivo grade
Recombinant anti-mouse PD-L1 antibodies (Clone 10F.9G2.1), In vivo grade
Recombinant anti-mouse PD-1 / PD-1 bispecific antibodies (Clone RMP1-14.1 / 29F.1A12.1), In vivo grade
Recombinant anti-mouse PD-1 / PD-1 bispecific antibodies (Clone 29F.1A12.1 / RMP1-14.1), In vivo grade
Recombinant anti-mouse PD-1 / PD-L1 bispecific antibodies (Clone RMP1-14.1 / 10F.9G2.1), In vivo grade
Recombinant anti-mouse PD-L1 / PD-1 bispecific antibodies (Clone 10F.9G2.1 / RMP1-14.1), In vivo grade
Recombinant anti-mouse PD-1 / PD-L1 bispecific antibodies (Clone 29F.1A12.1 / 10F.9G2.1), In vivo grade
Recombinant anti-mouse PD-L1 / PD-1 bispecific antibodies (Clone 10F.9G2.1 / 29F.1A12.1), In vivo grade

Anti-mouse CD279 (PD-1) Antibody (RMP1-14.1) from: Anti-mouse PD-1 Mouse Monoclonal Antibody PA007162.m2cLA Syd Labs

Ushelf Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

Q: which anti-mouse PD-1 clone is better for in vivo blockade?

Both RMP1-14 and 29F.1A12 are rat IgG2a monoclonal antibodies widely used for in vivo blockade of mouse PD-1 (programmed death-1, also known as CD279) in preclinical cancer immunotherapy and immune regulation studies. They function primarily by sterically blocking PD-1 interaction with its ligands (PD-L1 and PD-L2), thereby enhancing T cell responses.

There is no universal “best” clone, as choice depends on experimental goals, but supplier comparisons and cited studies highlight key differences:

Blocking Affinity and Potency

• 29F.1A12 is frequently described as superior for PD-1 blockade due to ~100-fold higher binding affinity and blocking capacity compared to RMP1-14. It achieves effective blockade at lower concentrations and more closely mimics the high-affinity profile of human therapeutic anti-PD-1 antibodies.

Publication Record and Historical Use

• RMP1-14 remains the most cited and extensively used clone for in vivo PD-1 blockade, particularly in syngeneic tumor models. It has a longer track record in published studies demonstrating anti-tumor efficacy.

Depletion Concerns

• Both clones are rat IgG2a isotype, which shares Fc characteristics with known depleting antibodies. Some independent studies suggest potential partial depletion of PD-1^high (exhausted) T cells in certain contexts.
• For strictly non-depleting blockade, many suppliers recommend recombinant Fc-silent variants (e.g., mouse IgG1 D265A or LALAPG mutations) of either clone.

In practice, many researchers now favor 29F.1A12 (or its recombinant non-depleting variants) for pure, high-potency in vivo PD-1/CD279 blockade, especially in new studies, while RMP1-14 remains reliable for reproducibility with historical data. Always select based on your model and consult specific product datasheets.

Q: Is recombinant anti-mouse PD-1 (RMP1-14) non-depleting / blocking-only?

Recombinant anti-mouse PD-1 (programmed death-1, also known as CD279) monoclonal antibodies derived from the RMP1-14 clone are typically engineered with Fc-silencing mutations to function as non-depleting, blocking-only reagents for in vivo PD-1/PD-L pathway inhibition.

These modifications — commonly D265A (in mouse IgG1 or IgG2a isotypes) or LALA-PG (L234A/L235A/P329G) — eliminate binding to Fcγ receptors, abolishing effector functions such as ADCC and CDC. This design ensures pure steric blockade of PD-1 interaction with PD-L1/PD-L2 without depleting PD-1-expressing cells (e.g., activated or exhausted T cells), while also reducing immunogenicity compared to the original rat IgG2a format.

Common variants include:

• Recombinant Fc silent anti-mouse PD-1 antibody RMP1-14 clone with D265A mutation (mouse IgG2a or IgG1-based)
• Non-depleting anti-mouse CD279 monoclonal antibody featuring effectorless mouse IgG1e3 (D265A)
• In vivo grade recombinant anti-mouse PD-1/CD279 RMP1-14 with LALAPG mutations in mouse IgG2a or IgG2c

These Fc-engineered formats support repeated dosing in syngeneic tumor models or immune regulation studies, providing clean PD-1 blockade without Fc-mediated artifacts. The primary mechanism remains inhibition of PD-1 signaling to enhance T cell responses, making them preferred for preclinical immunotherapy research requiring precise, depletion-free checkpoint inhibition.